Removal of thallium by deferasirox in rats as biological model.
The present research aimed to characterize the potential efficiency of deferasirox in removing thallium after its administration for 30 days following two dose levels of 20 and 160 μm of thallium (III) chloride to male Wistar rats every day. After thallium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness, loss of hair and weight, were observed in animals. Deferasirox was given orally to different groups of rats for a period of one week immediately after thallium administration. After chelation therapy, animals were killed by exsanguination from the abdominal aorta, and then thallium and iron concentrations in various tissues were determined by standard addition method. The chelation therapy results showed that deferasirox was able to remove thallium ions from the body and clinical symptoms were also reduced.
Saljooghi
Amir Sh
ASh
Department of Chemistry, Shahid Bahonar University of Kerman, Faculty of Science, Kerman, Iran. amir.saljooghi@yahoo.com
Fatemi
S Jamiladin
SJ
D000818:Animals; D001565:Benzoates / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002614:Chelating Agents / Q000627:therapeutic use*; D015913:Chelation Therapy; D000077588:Deferasirox; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D000075322:Heavy Metal Poisoning; D007501:Iron / Q000097:blood; D008297:Male; D019216:Metals, Heavy / Q000097:blood; D011041:Poisoning / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013054:Spectrophotometry, Atomic; D013793:Thallium / Q000008:administration & dosage / Q000097:blood / Q000506:poisoning*; D014230:Triazoles / Q000627:therapeutic use*
D001565:Benzoates; D002614:Chelating Agents; D019216:Metals, Heavy; D014230:Triazoles; C027549:thallium chloride; D013793:Thallium; D007501:Iron; D000077588:Deferasirox